Technical Analysis for GILD - Gilead Sciences, Inc.

Grade Last Price % Change Price Change
grade A 72.66 -2.73% -2.04
GILD closed down 2.73 percent on Thursday, February 27, 2020, on 3.83 times normal volume. The bulls were able to push the stock to a new 52-week high.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical GILD trend table...

Date Alert Name Type % Chg
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New 52 Week Closing High Bullish -2.73%
180 Bullish Setup Bullish Swing Setup -2.73%
Wide Range Bar Range Expansion -2.73%
New 52 Week High Strength -2.73%
Upper Bollinger Band Walk Strength -2.73%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Medicine Chemistry Biopharmaceutical Diseases Infection Organic Chemistry Cystic Fibrosis Cardiovascular Diseases HIV Pulmonary Arterial Hypertension Hepatotoxins Respiratory Diseases Gilead Sciences Liver Disease Prodrugs AIDS Cytomegalovirus Retinitis Fungal Infections Tenofovir Disoproxil

Is GILD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 78.88
52 Week Low 60.89
Average Volume 13,435,884
200-Day Moving Average 65.59
50-Day Moving Average 66.23
20-Day Moving Average 68.17
10-Day Moving Average 69.58
Average True Range 2.63
ADX 20.73
+DI 38.78
-DI 15.73
Chandelier Exit (Long, 3 ATRs ) 70.98
Chandelier Exit (Short, 3 ATRs ) 70.74
Upper Bollinger Band 73.68
Lower Bollinger Band 62.65
Percent B (%b) 0.91
BandWidth 16.17
MACD Line 1.80
MACD Signal Line 1.18
MACD Histogram 0.6214
Fundamentals Value
Market Cap 94.89 Billion
Num Shares 1.31 Billion
EPS 9.21
Price-to-Earnings (P/E) Ratio 7.89
Price-to-Sales 3.57
Price-to-Book 4.49
PEG Ratio -1.08
Dividend 2.08
Dividend Yield 2.86%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 82.59
Resistance 3 (R3) 83.56 81.22 80.94
Resistance 2 (R2) 81.22 78.69 80.74 80.38
Resistance 1 (R1) 76.94 77.13 75.77 75.97 79.83
Pivot Point 74.60 74.60 74.02 74.12 74.60
Support 1 (S1) 70.32 72.07 69.15 69.35 65.49
Support 2 (S2) 67.98 70.51 67.50 64.94
Support 3 (S3) 63.70 67.98 64.39
Support 4 (S4) 62.73